Episode 50. The Immune System Needs to Calm Down: Pharmacologic Management with Tocilizumab and Baricitinib

Share:
Facebook
Twitter
LinkedIn
Email

Tocilizumab and Baricitinib Mechanisms of Action


COVID-19 Pathogenesis: Late COVID-19

In the late stage, pulmonary edema can fill the alveolar spaces with hyaline membrane formation, compatible with early-phase acute respiratory distress syndrome (ARDS).

Joost Wiersinga W. eta al. JAMA Review 2020 doi:10.1001/jama.2020.12839


The Road to COVID-19 EUA Approval

Tocilizumab

  • 1/8/2010 FDA approval for treatment of moderate to severe rheumatoid arthritis
  • 8/31/2017 FDA approval for treatment of CAR T cell-induced cytokine release syndrome
  • 6/24/2021 EUA authorization for COVID-19 hospitalized adults and children

Baricitinib

  • 6/1/2018 FDA approval for treatment of moderate to severe rheumatoid arthritis
  • 11/19/2020 EUA for baricitinib in combination with remdesivir for COVID-19 hospitalized adults and children

Tocilizumab: Key COVID-19 Trials


Baricitinib: Key COVID-19 Trial


Tocilizumab For Treatment of COVD-19

Baricitinib For Treatment of COVD-19


Baricitinib Dose Adjustments Due to Laboratory Abnormalities

FDA Emergency Use Authorization for Baricitinib 11/19/2020

ABOUT AUTHOR

Jimmy L. Pruitt III, PharmD, BCPS, BCCCP

The Pharm So Hard Podcast is a show focused primarily on emergency medicine and hospital pharmacy related topics. To empower healthcare providers with the knowledge and skills they need to provide evidence-based, safe care for critically ill patients.

Posted On

By

Categories

Share

Subscribe to our Newsletter

New Episodes on 1st, 2nd, 4th Tuedays

Stay Connected to Get The Latest Podcast Alerts

Want to learn more?

Pharmacy and Acute Care University

An e-learning platform that empowers healthcare providers with knowledge and skills so they can provide evidence-based, safe care for these types of patients.

Pin It on Pinterest

%d